When looking at Amrita’s diverse experience, it’s easy to imagine the impact she can create for an organization. A senior manager with our Healthcare practice, Amrita led a telehealth assessment that will help shape the American Optometry Association’s future strategic direction and create new service channels in the retail world. She was also the first senior manager to join our Minneapolis office as Charity Chief, helping shape altruistic efforts and drive meaningful charitable impacts for our communities.
A fast tracker and creative thought leader, Amrita combines proven innovation leadership with expertise spanning business model innovation, healthcare innovation, go to market strategies, medical devices, medtech incubation, digital health, healthcare ecosystem & integration, , customer experience, , international quality and regulatory and business transformation.
Having lived and worked in multiple countries, Amrita offers a unique global perspective that enables her to align growth opportunities with customer needs and business strategy.
Before joining our team, Amrita was a principle consultant with Delta Airlines leading their enterprise IT transformation through the Dojo – a Tech Accelerator. Prior to Delta, Amrita worked at Medtronic and was an expatriate leading Healthcare Innovation for Asia, developing innovative patient centric solutions for the Cardiac and Diabetes Care Pathways. She has bachelor’s degrees in accounting, finance and MIS from University of Minnesota and an MBA in strategy and international business from Hamline University.
What makes Amrita different
The same curiosity and drive that make Amrita successful in business inspired her to climb to Mount Everest’s base camp. She also has an artistic side that she expresses through painting, working with fused glass and designing slow fashion using sustainable handloom textiles.
Where Amrita makes an impact
Amrita volunteers in an advisory capacity with KARO, a not-for-profit organization that provides financial and emotional aid toward medical treatment of cancer for young pediatric patients (up to age 23) in need.